Esketamine
- Generic Name
- Esketamine
- Brand Names
- Spravato
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16ClNO
- CAS Number
- 33643-46-8
- Unique Ingredient Identifier
- 50LFG02TXD
- Background
Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
Esketamine is the s-enantiomer of Ketamine. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970.
Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications and therapies. The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to take effect.
- Indication
Esketamine is indicated in combination with an oral antidepressant for the treatment of treatment-resistant depression in adults. It is also indicated for the treatment of depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behaviour.
- Associated Conditions
- Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Pain
- Associated Therapies
- Intubation
Postoperative Analgesic Effect of Esketamine
- Conditions
- Gynecological; Surgery (Previous), Affecting Fetus or Newborn, Due to Obstructed LaborAnalgesia
- Interventions
- Drug: 0.25mg/kg of esketamine in combination with 2 mg morphine sulfateDrug: 0.25mg/kg of esketamine in combination with 1 mg morphine sulfateDrug: 2 mg morphine sulfate
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Xuanhan County People's Hospital
- Target Recruit Count
- 119
- Registration Number
- NCT05582135
- Locations
- 🇨🇳
Qijun Ran, Dazhou, Sichuan, China
KetaMoHydBup: Pharmacokinetic Interaction of S-ketamine, Morphine, Hydromorphone and Buprenorphine
- Conditions
- The Effect of S-ketamine on Pharmacokinetics of Morphine, Hydromorphone, and Buprenorphine
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Elina Brinck
- Target Recruit Count
- 12
- Registration Number
- NCT05571176
VA Aripiprazole vs Esketamine for Treatment Resistant Depression
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- VA Office of Research and Development
- Registration Number
- NCT05554627
- Locations
- 🇺🇸
Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States
🇺🇸New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States
🇺🇸Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States
Comparison of Analgesic and Sedative Effects of Esmketamine and Remifentanil Combined With Propofol Respectively in Septic Shock Patients With Invasive Mechanical Ventilation
- Conditions
- Patients With Septic Shock Admitted to the ICU on Invasive Mechanical Ventilation
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 120
- Registration Number
- NCT05551910
Use of Oxycodone in Bariatric Surgery
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Qiang Fu
- Target Recruit Count
- 90
- Registration Number
- NCT05515822
The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease
- Conditions
- DepressionCrohn DiseaseEsketamine
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 120
- Registration Number
- NCT05506787
- Locations
- 🇨🇳
Anesthesiology Department, Jinling Hospital Affiliated to Nanjing University, Nanjing, Jiangsu, China
Safety and Efficacy of Esketamine Combined With Dexmedetomidine for Sedation of Mechanically Ventilated Patients
- Conditions
- AnalgesiaMechanical VentilationDexmedetomidineKetamineIntensive Care Units
- Interventions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-05-07
- Target Recruit Count
- 100
- Registration Number
- NCT05466708
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Esketamine Induction Intubation in ICU Patients.
- Conditions
- Critically Ill Patients
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 100
- Registration Number
- NCT05464979
- Locations
- 🇨🇳
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2023-08-16
- Target Recruit Count
- 80
- Registration Number
- NCT05458453
- Locations
- 🇨🇳
Department of Anesthesiology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳The Second Affiliated Hospital, Chongqing Medical University, Chongqing, Chongqing, China
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05450432
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.